Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed ...
Q3 2026
Feb 3, 2026
Q2 2026
Nov 6, 2025
Q1 2026
Aug 7, 2025
FY 2025
May 22, 2025
Q4 2025